Twist Bioscience Co. (NASDAQ:TWST) Receives $50.40 Consensus Target Price from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $50.40.

A number of research firms have recently weighed in on TWST. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird decreased their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Finally, Guggenheim reissued a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th.

Insider Buying and Selling

In related news, insider Dennis Cho sold 689 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider now owns 110,849 shares in the company, valued at $4,173,464.85. The trade was a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Laponis sold 936 shares of the company’s stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $27,846.00. Following the transaction, the chief financial officer now owns 106,018 shares in the company, valued at $3,154,035.50. This represents a 0.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,920 shares of company stock valued at $814,067 over the last 90 days. 3.01% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after acquiring an additional 189,791 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Twist Bioscience by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company’s stock worth $1,761,000 after acquiring an additional 9,722 shares during the last quarter. KBC Group NV grew its position in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares in the last quarter. Teacher Retirement System of Texas grew its position in Twist Bioscience by 18.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company’s stock worth $807,000 after purchasing an additional 2,755 shares in the last quarter. Finally, Stifel Financial Corp grew its position in Twist Bioscience by 19.6% in the 4th quarter. Stifel Financial Corp now owns 8,331 shares of the company’s stock worth $387,000 after purchasing an additional 1,364 shares in the last quarter.

Twist Bioscience Trading Down 0.3%

Shares of TWST stock opened at $33.52 on Friday. The firm has a 50 day moving average price of $34.05 and a two-hundred day moving average price of $41.62. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.01 billion, a PE ratio of -9.92 and a beta of 2.38. Twist Bioscience has a 12-month low of $27.12 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. As a group, analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.